Posted by Michael Wonder on 03 Feb 2022
ICER to assess treatments for amyotrophic lateral sclerosis
3 February 2022 - Report will be subject of Midwest CEPAC meeting in August 2022; draft scoping document open to public comment until 24 February 2022.
The Institute for Clinical and Economic Review announced today that it will assess the comparative clinical effectiveness and value of AMX0035 (Amylyx Pharmaceuticals) and oral edaravone (Mitsubishi Tanabe Pharma) for the treatment of amyotrophic lateral sclerosis.
